From chemoprevention to chemotherapy: Common targets and common goals

Expert Opinion on Investigational Drugs

Volumn 13, Issue 10, 2004, Pages 1327-1338

  Aggarwal, Bharat B ^a   Takada, Yasunari ^a   Oommen, Oommen V ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF KERALA   (India)

Author keywords

Chemoprevention; Inflammation; NF B; Phytochemical; Therapeutic; Tumorigenesis

Indexed keywords

ALLICIN; ANETHOLE; BETULIC ACID; CAPSAICIN; CATECHIN; CELL ADHESION MOLECULE; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; CYSTEINE DERIVATIVE; ELLAGIC ACID; EUGENOL; FLAVOPIRIDOL; GELATINASE B; GENISTEIN; GINGEROL; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; JANUS KINASE; LYCOPENE; PHOSPHATIDYLINOSITOL 3 KINASE; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; RESVERATROL; SILYMARIN; TRANSCRIPTION FACTOR AP 1; UROKINASE; URSOLIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; DOWN REGULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CHEMOPREVENTION; CYCLOOXYGENASE 2; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY; GROWTH SUBSTANCES; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHARMACEUTICAL PREPARATIONS; STAT TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 5444230182     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.10.1327     Document Type: Review

References (122)

1. GORMAN C, PARK A: The fires within. Time (2004) 42-46.
2. COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420(6917): 860-867.
3. BALKWILL F, MANTOVANI A: Inflammation and cancer: back to Virchow? Lancet (2001) 357 (9255):539-545.
4. YUSPA SH: Overview of carcinogenesis: past, present and future. Carcinogenesis (2000) 21 (3):341-344.
5. HONG WK, SPORN MB: Recent advances in chemoprevention of cancer. Science (1997) 278 (5340):1073-1077.
6. Prevention of cancer in the pext millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res. (1999) 59 (19):4743-4758.
7. SPORN MB, SUH N: Chemoprevention of cancer. Carcinogenesis (2000) 21 (3):525-530.
8. KELLOFF GJ: Perspectives on cancer chemoprevention research and drug development. Adv. Cancer Res. (2000) 78: 199-334.
9. CRAIG WJ: Phytochemicals: guardians of out health. J. Am. Diet. Assoc. (1997) 97 (10 Suppl. 2):S199-204.
10. CRAIG WJ: Health-promoting properties of common herbs. Am. J. Clin. Nutr. (1999) 70 (3 Suppl.):491S-499S.
11. SURH YJ: Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer (2003) 3 (10):768-780.
12. NEWMAN DJ, CRAGG GM, SNADER KM: Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. (2003) 66 (7):1022-1037.
13. KELLOFF GJ, BOONE CW, CROWELL JA et al.: New agents for cancer chemoprevention. J. Cell. Biochem. Suppl. (1996) 26: 1-28.
14. GARG A, AGGARWAL BB: Nuclear transcription factor-κB as a target for cancer drug development. Leukemia (2002) 16(6): 1053-1068.
15. AGGARWAL BB, TAKADA Y, SHISHODIA S et al.: Nuclear transcription factor NF-κB: Role in biology and medicine. Indian J. Exp. Biol. (2004) 42: 341-353.
16. KARALIS KP, VENIHAKI M, ZHAO J, VAN VLERKEN LE, CHANDRAS C: NF-κB participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J. Biol. Chem. (2004) 279(12): 10837-10840.
17. YEH SH, LIN CH, LEE CF, GEAN PW: A requirement of nuclear factor-κB activation in fear-potentiated startle. J. Biol. Chem. (2002) 277 (48):46720-46729.
18. KUMAR A, DHAWAN S, HARDEGEN NJ, AGGARWAL BB: Curcumin (Diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochem. Pharmacol. (1998) 55(6): 775-783.
19. LIN YL, LIN JK: (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB. Mol. Pharmacol. (1997) 52 (3):465-472.
20. MANNA SK, MUKHOPADHYAY A, VAN NT, AGGARWAL BB: Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase and apoptosis. J. Immunol. (1999) 163 (12 ):6800-6809.
21. NATARAJAN K, MANNA SK, CHATURVEDI MM, AGGARWAL BB: Protein tyrosine kinase inhibitors block tumor necrosis factor-induced activation of nuclear factor-κB, degradation of IκBα, nuclear translocation of p65 and subsequent gene expression. Arch. Biochem. Biophys. (1998) 352 (1):59-70.
22. NATARAJAN K, SINGH S, BURKE TR Jr, GRUNBERGER D, AGGARWAL BB: Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB. Proc Natl Acad Sci USA (1996) 93 (17):9090-9095.
23. CHAINY GB, MANNA SK, CHATURVEDI MM, AGGARWAL BB: Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-κB, AP-1, JNK, MAPKK and apoptosis. Oncogene (2000) 19 (25):2943-2950.
24. SINGH S, NATARAJAN K, AGGARWAL BB: Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-κB activation by diverse agents. J. Immunol. (1996) 157 (10):4412-4420.
25. MANNA SK, MUKHOPADHYAY A, AGGARWAL BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-κB, activator protein-1 and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J. Immunol. (2000) 164 (12):6509-6519.
26. SHAULIAN E, KARIN M: AP-1 as a regulator of cell life and death. Nat. Cell Biol. (2002) 4 (5):E131-136.
27. YOUNG MR, YANG HS, COLBURN NH: Promising molecular targets for cancer prevention: AP-1, NF-κB and Pdcd4. Trends Mol. Med. (2003) 9 (1):36-41.
28. SHAULIAN E, KARIN M: AP-1 in cell proliferation and survival. Oncogene (2001) 20 (19):2390-2400.
29. BIERHAUS A, ZHANG Y, QUEHENBERGER P et al.: The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-κB. Thromb. Haemost. (1997) 77 (4):772-782.
30. SATO T, KOIKE L, MIYATA Y et al.: Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res. (2002) 62 (4):1025-1029.
31. DONG Z, MA W, HUANG C, YANG CS: Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Cancer Res. (1997) 57 (19):4414-4419.
32. CHUNG JY, HUANG C, MENG X, DONG Z, YANG CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. (1999) 59 (18):4610-4617.
33. DING M, LU Y, BOWMAN L et al.: Inhibition of AP-1 and neoplastic transformation by fresh apple peel extract. J. Biol. Chem. (2004) 279 (11):10670-10676.
34. AGGARWAL BB, KUMAR A, BHARTI AC: Anticancer potential of curcumin: preclinical and clinical studies. Anti-Cancer Res. (2003) 23 (1A):363-398.
35. ANTO RJ, MUKHOPADHYAY A, DENNING K, AGGARWAL BB: Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis (2002) 23 (1):143-150.
36. JANA NR, DIKSHIT P, GOSWAMI A, NUKINA N: Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. (2004) 279 (12):11680-11685.
37. AGGARWAL BB, BHARDWAJ A, AGGARWAL RS et al.: Role of resveratrol in prevention and therapy of cancer: preclinical and Clinical Studies. Anti-Cancer Res. (2004)
38. GUPTA S, HASTAK K, AFAQ F, AHMAD N, MUKHTAR H: Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor κB and induction of apoptosis. Oncogene (2004) 23 (14):2507-2522
39. SHISHODIA S, AGGARWAL BB: Nuclear factor-κB activation: a question of life and death. J. Biochem. Mol. Biol. (2002) 35: 28-40.
40. ESTEVE PO, CHICOINE E, ROBLEDO O et al.: Protein kinase C-zeta regulates transcription of the matrix metalloproteinase-9 gene induced by IL-1 and TNF-α in glioma cells via NF-κB. J. Biol. Chem. (2002) 277 (38):35150-35155.
41. YAMAMOTO K, ARAKAWA T, UEDA N, YAMAMOTO S: Transcriptional roles of nuclear factor κB and nuclear factor-interleukin-6 in the tumor necrosis factor α-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J. Biol. Chem. (1995) 270 (52):31315-31320.
42. GUTTRIDGE DC, ALBANESE C, REUTHER JY, PESTELL RG, BALDWIN AS, JR.: NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol. Cell. Biol. (1999) 19 (8):5785-5799.
43. ZHU L, FUKUDA S, CORDIS G, DAS DK, MAULIK N: Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett. (2001) 508 (3):369-374.
44. CHU ZL, McKINSEY TA, LIU L et al.: Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proc. Natl. Acad. Sci. USA (1997) 94 (19):10057-10062.
45. YOU M, KU PT, HRDLICKOVA R, BOSE HR, JR.: Ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol. Cell. Biol. (1997) 17 (12):7328-7341.
46. TAMATANI M, CHE YH, MATSUZAKI H et al.: Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFκB activation in primary hippocampal neurons. J. Biol. Chem. (1999) 274 (13):8531-8538.
47. GRUMONT RJ, ROURKE IJ, GERONDAKIS S: Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev. (1999) 13 (4 ):400-411.
48. ZONG WX, EDELSTEIN LC, CHEN C, BASH J, GELINAS C: The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. (1999) 13 (4):382-387.
49. SCHWENZER R, SIEMIENSKI K, LIPTAY S et al.: The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-κB and c-Jun N-terminal kinase. J. Biol. Chem. (1999) 274 (27):19368-19374.
50. KREUZ S, SIEGMUND D, SCHEURICH P, WAJANT H: NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell Biol. (2001) 21 (12):3964-3973.
51. BHARTI AC, DONATO N, SINGH S, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003) 101 (3):1053-1062.
52. AGGARWAL S, TAKADA Y, SINGH S, MYERS J, AGGARWAL BB: Inhibition of growth and survival of human head neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signalling. Int. J. Cancer (2004) 111 (5):679-692
53. FULDA S, DEBATIN KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. (2004) 64 (1):337-346.
54. HAYASHIBARA T, YAMADA Y, NAKAYAMA S et al.: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr. Cancer (2002) 44 (2):193-201.
55. TYAGI AK, SINGH RP, AGARWAL C, CHAN DC, AGARWAL R: Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest and apoptosis. Clin. Cancer Res. (2002) 8 (11):3512-3519.
56. MASUDA M, SUZUI M, WEINSTEIN IB: Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. (2001) 7 (12):4220-4229.
57. CARPENTER G: The EGF receptor: a nexus for trafficking and signaling. Bioessays (2000) 22 (8):697-707.
58. YARDEN Y, SLIWKOWSKI MX: Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. (2001) 2 (2):127-137.
59. SCHLESSINGER J: Signal transduction. Autoinhibition control. Science (2003) 300 (5620):750-752.
60. RUSCH V, KLIMSTRA D, VENKATRAMAN E et al.: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. (1997) 3 (4):515-522.
61. DANCEY JE: Predictive factors for epidermal growth factor receptor inhibitors- the bull's-eye hits the arrow. Cancer Cell (2004) 5 (5):411-415.
62. GAUR U, AGGARWAL BB: Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. (2003) 66 (8):1403-1408.
63. ESTROV Z, SHISHODIA S, FADERL S et al.: Resveratrol blocks interleukin-1β-induced activation of the nuclear transcription factor NF-κB, inhibits proliferation, causes S-phase arrest and induces apoptosis of acute myeloid leukemia cells. Blood (2003) 102 (3):987-995.
64. BHARTI AC, DONATO N, AGGARWAL BB: Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J. Immunol. (2003) 171 (7):3863-3871.
65. DORAI T, GEHANI N, KATZ A: Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol. Urol. (2000) 4 (1):1-6.
66. HONG RL, SPOHN WH, HUNG MC: Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin. Cancer Res. (1999) 5 (7):1884-1891.
67. SAH JF, BALASUBRAMANIAN S, ECKERT RL, RORKE EA: Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway: Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. (2004) 279 (13):12755-12762.
68. CHUNG JY, PARK JO, PHYU H, DONG Z, YANG CS: Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3′-digallate. FASEB J. (2001) 15 (11):2022-2024.
69. DARNELL JE, JR., KERR IM, STARK GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 264 (5164):1415-1421.
70. TURKSON J, JOVE R: STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 19 (56):6613-6626.
71. NATARAJAN C, BRIGHT JJ: Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. (2002) 168 (12):6506-6513.
72. KIM HY, PARK EJ, JOE EH, JOU I: Curcumin suppresses Janus kinase-STAT inflammatory signaling through activation of Src homology 2 domain-containing tyrosine phosphatase 2 in brain microglia. J. Immunol. (2003) 171 (11):6072-6079.
73. BHARTI AC, SHISHODIA S, REUBEN JM et al.: Nuclear factor-{κ}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients and their suppression leads to apoptosis. Blood (2003).
74. ZHOU G, KUO MT: NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol Chem. (1997) 272 (24):15174-15183.
75. ANUCHAPREEDA S, LEECHANACHAI P, SMITH MM, AMBUDKAR SV, LIMTRAKUL PN: Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. (2002) 64 (4):573-582.
76. HONG J, LAMBERT JD, LEE SH, SINKO PJ, YANG CS: Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem. Biophys. Res. Commun. (2003) 310 (1):222-227.
77. JODOIN J, DEMEULE M, BELIVEAU R: Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim. Biophys. Acta (2002) 1542 (1-3):149-159.
78. GASPARINI G, LONGO R, SARMIENTO R, MORABITO A: Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. (2003) 4 (10):605-615.
79. ANTO RJ, MUKHOPADHYAY A, SHISHODIA S, GAIROLA CG, AGGARWAL BB: Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of Iκ B(α): correlation with induction of cyclooxygenase-2. Carcinogenesis (2002) 23 (9):1511-1518.
80. KUWANO T, NAKAO S, YAMAMOTO H et al.: Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. FASEB J. (2004) 18 (2):300-310.
81. FLOWER RJ: The development of COX2 inhibitors. Nat. Rev. Drug Discov. (2003) 2 (3):179-191.
82. PLUMMER SM, HOLLOWAY KA, MANSON MM et al.: Inhibition of cyclooxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK /IKK signalling complex. Oncogene (1999) 18 (44):6013-6020.
83. SUBBARAMAIAH K, CHUNG WJ, MICHALUART P et al.: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. (1998) 273 (34):21875-21882.
84. SHISHODIA S, MAJUMDAR S, BANERJEE S, AGGARWAL BB: Ursolic acid inhibits nuclear factor-κB activation induced by carcinogenic agents through suppression of IκBα kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9 and cyclin D1. Cancer Res. (2003) 63 (15):4375-4383.
85. TAKADA Y, AGGARWAL BB: Flavopiridol inhibits NF-κB activation induced by various carcinogens and inflammatory agents through inhibition of IκBα kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2 and matrix metalloprotease-9. J. Biol. Chem. (2004) 279 (6):4750-4759.
86. TAKADA Y, AGGARWAL BB: Betulinic acid suppresses carcinogen-induced NF-κB activation through inhibition of Iκ Bα kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. J. Immunol. (2003) 171 (6 ):3278-3286.
87. FOLKMAN J, KAIPAINEN A: Genes tell lymphatics to sprout or not. Nat. Immunol. (2004) 5 (1):11-12.
88. ARBISER JL, KLAUBER N, ROHAN R et al.: Curcumin is an in vivo inhibitor of angiogenesis. Mol. Med. (1998) 4 (6):376-383.
89. MOHAN R, SIVAK J, ASHTON P et al.: Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix mctalloproteinase gelatinase B. J. Biol. Chem. (2000) 275 (14):10405-10412.
90. KIM JH, SHIM JS, LEE SK et al.: Microarray-based analysis of antiangiogenic activity of demethoxycurcumin on human umbilical vein endothelial cells: crucial involvement of the down-regulation of matrix metalloproteinase. Jpn J. Cancer Res. (2002) 93 (12):1378-1385.
91. TSENG SH, LIN SM, CHEN JC et al.: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. (2004) 10 (6):2190-2202.
92. LIN MT, YEN ML, LIN CY, KUO ML: Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol. Pharmacol. (2003) 64 (5):1029-1036.
93. BRAKENHIELM E, CAO R, CAO Y: Suppression of angiogenesis, tumor growth and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. (2001) 15 (10):1798-1800.
94. LEE YK, BONE ND, STREGE AK, JELINEK DF, KAY NE: VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG) in B cell chronic lymphocytic leukemia. Blood (2004) 104 (3):788-794.
95. LAMY S, GINGRAS D, BELIVEAU R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. (2002) 62 (2):381-385.
96. MOTOKURA T, BLOOM T, KIM HG et al.: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature (1991) 350 (6318):512-515.
97. MUKHOPADHYAY A, BANERJEE S, STAFFORD LJ et al.: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene (2002) 21 (57):8852-8861.
98. SHISHODIA S, POTDAR P, GAIROLA CG, AGGARWAL BB: Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis (2003) 24 (7):1269-1279.
99. AHMAD N, ADHAMI VM, AFAQ F, FEYES DK, MUKHTAR H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin. Cancer Res. (2001) 7 (5):1466-1473.
100. WOLTER F, AKOGLU B, CLAUSNITZER A, STEIN J: Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J. Nutr. (2001) 131 (8):2197-2203.
101. JOE AK, LIU H, SUZUI M et al.: Resveratrol induces growth inhibition, S-phase arrest, apoptosis and changes in biomarker expression in several human cancer cell lines. Clin. Cancer Res. (2002) 8 (3):893-903.
102. GUPTA S, HUSSAIN T, MUKHTAR H: Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch. Biochem. Biophys. (2003) 410 (1):177-185.
103. ZI X, AGARWAL R: Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc. Natl. Acad. Sci. USA (1999) 96 (13):7490-7495.
104. DUVOIX A, SCHMITZ M, SCHNEKENBURGER M et al.: Transcriptional regulation of glutathione S-transferase P1-1 in human leukemia. Biofactors (2003) 17 (1-4):131-138.
105. DUVOIX A, MORCEAU F, DELHALLE S et al.: Induction of apoptosis by curcumin: mediation by glutathione S-transferase P1-1 inhibition. Biochem. Pharmacol. (2003) 66 (8):1475-1483.
106. AWASTHI S, PANDYA U, SINGHAL SS et al.: Curcumin-glutathione interactions and the role of human glutathione S-transferase P1-1. Chem. Biol. Interact. (2000) 128 (1):19-38.
107. KUBOTA T, UEMURA Y, KOBAYASHI M, TAGUCHI H: Combined effects of resveratrol and paclitaxel on lung cancer cells. Anti-Cancer Res. (2003) 23 (5A):4039-4046.
108. JAZIREHI AR, BONAVIDA B: Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. (2004) 3 (1):71-84.
109. HARBOTTLE A, DALY AK, ATHERTON K, CAMPBELL FC: Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int. J. Cancer (2001) 92 (6):777-783.
110. SADZUKA Y, SUGIYAMA T, SONOBE T: Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol. Lett. (2000) 114 (1-3):155-162.
111. SADZUKA Y, SUGIYAMA T, HIROTA S: Modulation of cancer chemotherapy by green tea. Clin. Cancer Res. (1998) 4 (1):153-156.
112. DHANALAKSHMI S, AGARWAL P, GLODE LM, AGARWAL R: Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int. J. Cancer (2003) 106 (5):699-705.
113. WANG CY, CUSACK JC Jr, LIU R, BALDWIN AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. (1999) 5 (4):412-417.
114. CLEMENT MV, HIRPARA JL, CHAWDHURY SH, PERVAIZ S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood (1998) 92 (3):996-1002.
115. CHEN X, SHEN B, XIA L et al.: Activation of nuclear factor κB in radioresistance of TP53-inactive human keratinocytes. Cancer Res. (2002) 62 (4):1213-1221.
116. TAMATANI T, AZUMA M, ASHIDA Y et al.: Enhanced radiosensitization and chemosensitization in NF-κB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int. J. Cancer (2004) 108 (6):912-921.
117. CHENDIL D, RANGA RS, MEIGOONI D, SATHISHKUMAR S, AHMED MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene (2004) 23 (8):1599-1607.
118. CATALDI A, CENTURIONE L, DI PIETRO R et al.: Protein kinase C-ζ nuclear translocation mediates the occurrence of radioresistance in friend erythroleukemia cells. J. Cell. Biochem. (2003) 88 (1):144-151.
119. VARADKAR P, DUBEY P, KRISHNA M, VERMA N: Modulation of radiation-induced protein kinase C activity by phenolics. J. Radiol. Prot (2001) 21 (4):361-370.
120. BENOWITZ S: Technology Motivating Industry. Scientist (1996) 10: 1-7.
121. BENOWITZ S, REYNOLD T: J. Natl. Cancer Inst. (1991) 183: 594.
122. SOMASUNDARAM S, EDMUND NA, MOORE DT et al.: Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. (2002) 62 (13):3868-3875.